tert-butyl 3-oxo-3-(prop-2-ynylamino)propylcarbamate | 478843-29-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl 3-oxo-3-(prop-2-ynylamino)propylcarbamate
• 英文别名: tert-butyl (3-oxo-3-(prop-2-yn-1-ylamino)propyl)carbamate；tert-butyl N-{2-[(prop-2-yn-1-yl)carbamoyl]ethyl}carbamate；tert-butyl N-[3-oxo-3-(prop-2-ynylamino)propyl]carbamate
• CAS: 478843-29-7
• 化学式: C₁₁H₁₈N₂O₃
• 分子量: 226.276
• InChiKey: RAWDIMGGRVVQTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-oxo-3-(prop-2-ynylamino)propylcarbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 以88%的产率得到3-amino-N-(prop-2-ynyl)propanamide
  参考文献：
  名称：

  Evaluation of the antibacterial and antibiofilm activities of novel CRAMP–vancomycin conjugates with diverse linkers

  摘要：

  CRAMP（与抗菌肽相关的防御素）和万古霉素的共轭物通过使用多样的亲水性和疏水性连接剂进行点击化学合成。

  DOI：

  10.1039/c5ob00830a
• 作为产物：
  描述：

  Boc-beta-丙氨酸 、 炔丙胺 在 N-甲基吗啉 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以87%的产率得到tert-butyl 3-oxo-3-(prop-2-ynylamino)propylcarbamate
  参考文献：
  名称：

  Evaluation of the antibacterial and antibiofilm activities of novel CRAMP–vancomycin conjugates with diverse linkers

  摘要：

  CRAMP（与抗菌肽相关的防御素）和万古霉素的共轭物通过使用多样的亲水性和疏水性连接剂进行点击化学合成。

  DOI：

  10.1039/c5ob00830a

文献信息

• Evaluation of the antibacterial and antibiofilm activities of novel CRAMP–vancomycin conjugates with diverse linkers
  作者：Nigam M. Mishra、Yves Briers、Chris Lamberigts、Hans Steenackers、Stijn Robijns、Bart Landuyt、Jos Vanderleyden、Liliane Schoofs、Rob Lavigne、Walter Luyten、Erik V. Van der Eycken

  DOI：10.1039/c5ob00830a

  日期：——

  Conjugates of CRAMP (cathelicidin-related antimicrobial peptides) and vancomycin were synthesised using click chemistry with diverse hydrophilic and hydrophobic linkers.

  CRAMP（与抗菌肽相关的防御素）和万古霉素的共轭物通过使用多样的亲水性和疏水性连接剂进行点击化学合成。
• [EN] CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] PYRIMIDINES CYCLOALKYLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222363A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题涉及Formula I或I'的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁过载状态，如地中海贫血、镰状细胞病和血色病，以及肾脏损伤。
• 알카인을 이용한 아마이드 화합물의 제조방법 및 이를 이용한 펩타이드 제조 방법
  申请人：Seoul National University R&DB Foundation 서울대학교산학협력단(120070509242) Corp. No ▼ 114371-0009224BRN ▼119-82-03684

  公开号：KR20170011773A

  公开（公告）日：2017-02-02

  본 발명은 전이금속촉매의 존재 하에 알카인 및 N-하이드록시 화합물을 유기용매 내에서 교반하여 아마이드 결합을 형성시키는 단계를 포함하는 아마이드 화합물의 제조방법 및 이를 이용한 펩타이드 제조방법에 관한 것으로, 본 발명에 의한 아마이드화 반응은 기존의 단순한 친핵성 및 친전자성과 같은 극성 반응성에 의존하지 않고 알카인과 전이금속의 배위결합 반응성에서 도출된 반응을 기반으로 하여 탁월한 화학선택성을 나타낸다. 또한, 펩타이드 합성시 소모적인 보호기 부착 및 탈착 반응 단계를 필요로 하지 않고 반응공정이 간단하여 폴리펩타이드 계열의 화합물을 합성하는데 매우 효과적일 뿐 아니라 반응 도중 출발물질이 소실되지 않기 때문에 100%의 원자경제성을 갖는다.

  This invention relates to a method for producing amide compounds, which includes a step of stirring alkaline and N-hydroxy compounds in an organic solvent under the presence of a transition metal catalyst to form amide bonds, and a peptide production method using the same. The amide reaction according to the present invention is based on the reactivity derived from the coordination reaction between alkaline and transition metals, rather than relying on conventional polar reactions such as simple nucleophilic and electrophilic reactions, demonstrating excellent chemical selectivity. Furthermore, the peptide synthesis process does not require consuming protective group attachment and detachment reactions, and the reaction process is simple, making it very effective for synthesizing compounds in the polyamide series, while also maintaining 100% atom efficiency as the starting materials are not lost during the reaction.
• [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222483A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁超载状态，如地中海贫血、镰状细胞病和血色病，以及肾损伤。
• Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis
  作者：Mikhail Krasavin、Alexei Lukin、Tatiana Vedekhina、Olga Manicheva、Marine Dogonadze、Tatiana Vinogradova、Natalia Zabolotnykh、Elizaveta Rogacheva、Liudmila Kraeva、Piotr Yablonsky

  DOI：10.1016/j.ejmech.2018.08.068

  日期：2018.9

  Within the general nitrofuran carboxamide chemotype, chimera derivatives incorporating diversely substituted imidazoles attached via an alkylamino linker were synthesized. Antimycobacterial evaluation against drug-sensitive M. tuberculosis H37Rv strain identified five active druglike compounds which were further profiled against patient-derived M. tuberculosis strains in vitro. One of the compounds

  在一般的硝基呋喃羧酰胺化学型中，合成了通过烷基氨基连接基结合了各种取代的咪唑的嵌合衍生物。对药物敏感的结核分枝杆菌H37Rv菌株的抗分枝杆菌鉴定鉴定出了五种活性药物样化合物，这些化合物在体外进一步针对患者衍生的结核分枝杆菌菌株进行了分析。这些化合物中的一种显示出对此类菌株之一的有希望的强效活性（MIC 0.8μg/ mL），这些菌株否则会对诸如链霉素，异烟肼，利福平，乙胺丁醇，卡那霉素，乙乙酰胺，卡普霉素和阿米卡星等一线和二线TB治疗产生耐药性。该化合物对小鼠具有低毒性（LD 50 （＝ 900.0±83.96mg / kg），并且在药物敏感性结核的小鼠模型中对乙胺丁醇和在被MDR结核感染的小鼠中对神经毒性的环丝氨酸具有相似的效力。